Overview

Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study

Status:
Withdrawn
Trial end date:
2013-01-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of this observational study is to compare the use of an extended release paracetamol formulation with standard paracetamol in a cohort of Australian concessional patients with osteoarthritis (OA), to assess differences in prescribing patterns and patient compliance.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Acetaminophen
Criteria
Inclusion Criteria:

- Participants prescribed with a paracetamol product and categorized as a concessional
patient

- Participants with new episodes of OA (no history of OA paracetamol in previous 12
months) or suffering from chronic OA (history of OA paracetamol in the previous 12
months)

Exclusion Criteria:

- Participants with Rheumatoid arthritis or other auto-immune inflammatory conditions

- Participants receiving the following anti-rheumatoid therapies:Immunimodulators such
as methotrexate, leflunamide and TNF blockers

- Participants receiving treatment for cancer pain